No benefit of clopidogrel added to ASA after lacunar infarct

In this large randomized trial of patients with a recent lacunar infarct, the addition of clopidogrel to ASA did not reduce the risk of recurrent stroke, but the risk of major bleeding was twice as high (2% vs 1% per year). There is no benefit, and there is harm, when clopidogrel is added to ASA after lacunar infarct (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment